LRMR vs. ANNX, FULC, CDMO, MRSN, TVTX, TBPH, NGNE, HRTX, OCS, and HROW
Should you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Annexon (ANNX), Fulcrum Therapeutics (FULC), Avid Bioservices (CDMO), Mersana Therapeutics (MRSN), Travere Therapeutics (TVTX), Theravance Biopharma (TBPH), Neurogene (NGNE), Heron Therapeutics (HRTX), Oculis (OCS), and Harrow Health (HROW). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.
Annexon received 13 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. Likewise, 71.93% of users gave Annexon an outperform vote while only 60.87% of users gave Larimar Therapeutics an outperform vote.
Annexon's return on equity of -38.83% beat Larimar Therapeutics' return on equity.
Annexon has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
Annexon currently has a consensus target price of $14.43, suggesting a potential upside of 224.24%. Larimar Therapeutics has a consensus target price of $18.50, suggesting a potential upside of 186.38%. Given Larimar Therapeutics' higher probable upside, equities analysts plainly believe Annexon is more favorable than Larimar Therapeutics.
In the previous week, Annexon had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 6 mentions for Annexon and 0 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.06 beat Annexon's score of 0.00 indicating that Annexon is being referred to more favorably in the media.
91.9% of Larimar Therapeutics shares are owned by institutional investors. 19.1% of Annexon shares are owned by company insiders. Comparatively, 4.3% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Larimar Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Summary
Annexon beats Larimar Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Larimar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Larimar Therapeutics Competitors List
Related Companies and Tools
